Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients

This study has been completed.
Sponsor:
Collaborators:
CancerCare Manitoba
Jewish General Hospital
Newfoundland Cancer Treatment & Research Foundation
Notre-dame Hospital
Ottawa Hospital Research Institute
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00168181
First received: September 9, 2005
Last updated: April 15, 2011
Last verified: April 2011
  Purpose

This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.


Condition Intervention Phase
Cancer
Head and Neck Cancer
Procedure: Submandibular gland Transfer
Drug: Salagen
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase III Randomized Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • To compare the efficacy of prevention of XRT induced xerostomia using two different approaches: oral Pilocarpine versus submandibular salivary gland transfer protocol; To compare the rate and severity of XRT induced xerostomia using these two strategies

Secondary Outcome Measures:
  • To evaluate the incidence of oral candidiasis, percutaneous endoscopic gastrostomy (PEG), and hospitalization during XRT

Estimated Enrollment: 220
Study Start Date: April 2002
Estimated Study Completion Date: April 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Previously untreated and confirmed histological diagnosis of squamous cell/adenoid cystic carcinoma of the oropharynx, hypopharynx, larynx, and patients with unknown primary tumor with metastases to the neck nodes and squamous cell carcinoma of the skin of head and neck region with ipsilateral neck nodes (more than one node) metastases.
  2. Radiation volume to encompass > or equal to 80% of major salivary glands (parotids and the non-transferred submandibular salivary gland) and have > or equal to 50 Gys delivered to that volume via external beam.
  3. Karnofsky performance score > or equal to 70
  4. Minimum age 18 years
  5. The patient must sign a study-specific informed consent prior to study entry
  6. Expected survival > or equal to one year

Exclusion Criteria:

  1. Carcinoma of nasopharynx, oral cavity, N3 disease, bilateral neck node involvement, pre-epiglottic space involvement, involvement of level 1 nodes on either side of the neck, and patients with post-operative recurrent disease.
  2. Salivary gland malignancy
  3. Salivary gland disease
  4. Use of anti-cholinergic drugs and tricyclic drugs
  5. Delay in XRT of more than 8 weeks following the curative surgery
  6. Pregnant or lactating females are not eligible. Patients of childbearing potential should agree to use an effective method of contraception
  7. Prior head and neck irradiation
  8. Recurrent disease
  9. Allergy to pilocarpine
  10. Patients with uncontrolled asthma, acute iritis, or narrow angle glaucoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00168181

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
CancerCare Manitoba
Jewish General Hospital
Newfoundland Cancer Treatment & Research Foundation
Notre-dame Hospital
Ottawa Hospital Research Institute
Investigators
Principal Investigator: Naresh Jha, MBBS AHS Cancer Control Alberta
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00168181     History of Changes
Other Study ID Numbers: HN-04-0010
Study First Received: September 9, 2005
Last Updated: April 15, 2011
Health Authority: Canada: Ethics Review Committee

Keywords provided by AHS Cancer Control Alberta:
salagen
gland transfer
randomized
xerostomia

Additional relevant MeSH terms:
Head and Neck Neoplasms
Xerostomia
Neoplasms by Site
Neoplasms
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Pilocarpine
Miotics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Muscarinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 14, 2014